港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

460.029

+35.4158.34%

漲家數：31

跌家數：2

平家數：1

市盈率：- -

高：463.604

開：425.923

低：425.923

收：424.614

資料載入中...

港股異動 | 再鼎醫藥(09688)漲超7% 瑞普替尼新適應症上市申請獲受理

雙面馬應龍：一邊業績迴歸增長，一邊深陷“迴流藥風波”

“風暴眼”中的鉅子生物：市場優勢漸失，至今未拿到Ⅲ類醫療器械批文

A股收評：三大指數漲跌不一離境退税概念股表現強勢

港股異動 | 諾誠健華(09969)漲超15% 新一代泛TRK抑制劑新藥上市申請獲受理公司未來催化劑豐富

醫藥股領漲，信達生物漲超10%，港股科技50ETF（159750）漲1.74%

A股午後醫藥板塊持續走高，創新藥方向繼續領漲，眾生藥業、華森製藥、富士萊漲停，百利天恆、諾誠健華、新諾威、百濟神州創歷史

瑞士製藥巨頭羅氏擬未來五年在美國投資500億美元

東曜藥業-B盤中異動下午盤股價大漲5.78%

羅氏將在5年內向美國製藥和診斷領域投資500億美元

环球市场播报

康寧傑瑞製藥-B盤中異動下午盤大幅上漲5.13%報6.970港元

【羅氏未來五年將在美國投資500億美元】羅氏將在未來五年在美國製藥和診斷領域投資500億美元。

《股市簡訊》中國康方生物一度跳漲6.5%，首個自身免疫性疾病藥物獲批上市

港股午評：恒生指數跌0.04% 黃金、創新藥板塊領漲

南方财经网

去年北京追回醫保基金4.64億元

國信證券：關注出海加速的創新藥以及政策支持的服務板塊

港股概念追蹤|生物醫藥去庫存週期尾聲原料藥+創新藥受益國產替代（附概念股）

A股創新藥板塊震盪走高，華納藥廠漲超10%，熱景生物漲超7%，東誠藥業、百利天恆、翰宇藥業跟漲。

沛嘉醫療-B盤中異動早盤股價大漲5.63%報4.880港元

港股創新藥50ETF(513780)漲超3%，多隻個股漲超10%！多款創新藥取得突破

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":460.02872,"timestamp":1745309290532,"preClose":424.61395,"halted":0,"volume":185824446,"delay":0,"changeRate":0.083405,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":35.414764,"latestTime":"04-22 16:00:00","open":425.9225,"high":463.60376,"low":425.9225,"amount":3929023020,"amplitude":0.088742,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"pbRate":3.545304,"peRate":-21.142926,"turnoverRate":0.007028,"increases":31,"decrements":2,"flats":0,"marketCap":265915581440,"floatMarketCap":245953733792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":463.60376,"amplitude":0.088742,"preClose":424.61395,"low":425.9225,"pbRate":"3.545304","latestPrice":460.02872,"volume":185824446,"delay":0,"open":425.9225,"prevYearClose":331.1933,"prevWeekClose":424.614,"prevMonthClose":455.082,"prevQuarterClose":455.082,"fiveDayClose":418.61,"twentyDayClose":454.409,"sixtyDayClose":319.608,"secType":"PLATE","market":"HK","turnoverRate":0.007028,"peRate":-21.142926,"marketCap":265915581440,"floatMarketCap":245953733792,"timestamp":1745309290532,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":31,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529345581","title":"港股異動 | 再鼎醫藥(09688)漲超7% 瑞普替尼新適應症上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529345581","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529345581?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 15:34","pubTimestamp":1745307273,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.02%，报24.4港元，成交额2.79亿港元。另外，公司合作伙伴argenx近日宣布，艾加莫德预充针皮下注射剂型获美国FDA批准上市。据悉，目前在国内，艾加莫德已有静脉输注和皮下注射2种给药方式。再鼎医药将于2025年在国内递交艾加莫德预充式皮下注射剂型的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","BK4588","BK4585","ZLAB","BK4548","BK1161","BK4526","BK1588","09688","LU2488822045.USD","BK4531"],"gpt_icon":0},{"id":"2529753343","title":"雙面馬應龍：一邊業績迴歸增長，一邊深陷“迴流藥風波”","url":"https://stock-news.laohu8.com/highlight/detail?id=2529753343","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529753343?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 15:25","pubTimestamp":1745306749,"startTime":"0","endTime":"0","summary":"2024年，有着“痔疮药第一股”之称的马应龙终于重回增长轨道。4月2日晚间，马应龙披露2024年业绩财报。只不过，当下的马应龙或许难以安心享受这份成绩单带来的喜悦，因为企业刚被卷入“回流药风波”。一般来说，“回流药”往往与欺诈骗保有关，而马应龙旗下药店也正在面临调查。在走过400余年历史之后，卷入“回流药风波”的马应龙如今又要开始苦恼，如何重建市场的信任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/255688","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2529343799","title":"“風暴眼”中的鉅子生物：市場優勢漸失，至今未拿到Ⅲ類醫療器械批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2529343799","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529343799?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 15:23","pubTimestamp":1745306606,"startTime":"0","endTime":"0","summary":"巨子生物旗下知名品牌可复美陷入一场成分“罗生门”。而这一被国家药监局明令禁止的成分，与巨子生物“未检出违禁成分”的官方回应形成尖锐对立。4月15日晚间，中国香料香精化妆品工业协会发布公告称，对可复美相关产品检测结果未见异常。2024年7月，“可复美”母公司巨子生物以“侵犯名誉权”为由将秦女士诉至法院，目前案件仍在审理中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/255681","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1100","09997","BK1207","SG9999004311.SGD","LU2488822045.USD","02367","BK1574","BK1583","BK1222","09996"],"gpt_icon":0},{"id":"2529310258","title":"A股收評：三大指數漲跌不一 離境退税概念股表現強勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2529310258","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529310258?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 15:05","pubTimestamp":1745305501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["601008","160636","01477","159792","BK0028","BK1574","BK0188","BK0000","BK1191","BK0205","BK0185","BK0012","159982","BK0010","399006","BK0047","BK0082","399001","600787","BK0016","BK0270","399300"],"gpt_icon":0},{"id":"2529311469","title":"港股異動 | 諾誠健華(09969)漲超15% 新一代泛TRK抑制劑新藥上市申請獲受理 公司未來催化劑豐富","url":"https://stock-news.laohu8.com/highlight/detail?id=2529311469","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529311469?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 14:08","pubTimestamp":1745302132,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华涨超15%，截至发稿，涨15.06%，报10.16港元，成交额4.21亿港元。消息面上，诺诚健华近日宣布，中国国家药品监督管理局药品审评中心已受理新一代泛TRK抑制剂Zurletrectinib用于治疗携带 NTRK融合基因的晚期实体瘤成人和青少年患者的新药上市申请。太平洋证券指出，公司未来12个月内公司催化剂丰富。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","BK1161","688428","09969"],"gpt_icon":0},{"id":"2529191223","title":"醫藥股領漲，信達生物漲超10%，港股科技50ETF（159750）漲1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529191223","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529191223?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:49","pubTimestamp":1745300963,"startTime":"0","endTime":"0","summary":"港股午后转涨，恒生指数涨0.6%，早盘一度跌近1%，医药股领涨，信达生物涨超10%，百济神州、康方生物、再鼎医药涨幅居前；互联网、芯片、汽车股纷纷跟涨，小米集团涨近6%，华虹半导体、零跑汽车涨超4%。港股科技50ETF涨1.74%，盘中成交超1亿元。截至发稿，南向资金净流入超78亿港元。港股科技50ETF已纳入融资融券标的，意味着ETF在在资产规模、持有人户数、流动性方面均满足了较高的市场要求，本身具备较高质地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.jrj.com.cn/2025/04/22134949743697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","09939","513980","BK1583","LU2328871848.SGD","BK1515","LU2488822045.USD","LU1969619763.USD","BK1589","01801","BK1574","159750","159938"],"gpt_icon":0},{"id":"2529701316","title":"A股午後醫藥板塊持續走高，創新藥方向繼續領漲，眾生藥業、華森製藥、富士萊漲停，百利天恆、諾誠健華、新諾威、百濟神州創歷史","url":"https://stock-news.laohu8.com/highlight/detail?id=2529701316","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529701316?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:47","pubTimestamp":1745300842,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002294","688506","688235","01349","BK0077","159992","688505","BK1583","ONC","159982","06160","LU1969619763.USD","BK1161","BK0196","301258","BK1500","09969","399300","BK0239","002317","688428","BK0187","688091","300765","BK1574","BK0226","BK1191","BK0028","LU0307460666.USD","159938","LU2328871848.SGD","BK4139","688068","BK1588","LU0588546209.SGD","002907","BK0183","BK1515","BK0188","09939","06978"],"gpt_icon":0},{"id":"2529319445","title":"瑞士製藥巨頭羅氏擬未來五年在美國投資500億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529319445","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529319445?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:38","pubTimestamp":1745300310,"startTime":"0","endTime":"0","summary":"罗氏集团周二表示，计划未来五年在美国投资500亿美元，这是迄今为止跨国公司为应对特朗普关税政策而宣布的在美国的最大的投资举措之一。这家瑞士制药巨头表示，这项投资将创造超过12000个新工作岗位，其中包括近6500个建筑工作岗位，以及1000个新建和扩建设施的工作岗位。\n\n\r\n            责任编辑：栎树","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/04/22133849743466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2529159073","title":"東曜藥業-B盤中異動 下午盤股價大漲5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529159073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529159073?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:16","pubTimestamp":1745298960,"startTime":"0","endTime":"0","summary":"2025年04月22日下午盘13时16分，东曜药业-B股票出现异动，股价大幅上涨5.78%。截至发稿，该股报1.830港元/股，成交量2.96万股，换手率0.00%，振幅6.36%。东曜药业-B股票所在的生物技术行业中，整体涨幅为4.67%。东曜药业-B公司简介：东曜药业股份有限公司是一家临床阶段生物制药公司,主要从事开发及商业化肿瘤药物及疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422131600974031a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422131600974031a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2529313168","title":"羅氏將在5年內向美國製藥和診斷領域投資500億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529313168","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529313168?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:09","pubTimestamp":1745298540,"startTime":"0","endTime":"0","summary":"跨国制药公司罗氏（Roche）在一份声明中表示，该公司承诺将在5年内投资500亿美元，包括在印第安纳州、宾夕法尼亚州、马萨诸塞州和加利福尼亚州新建和扩建生产设施，以及即将公布的其他生产地点。这些投资将创造逾1.2万个新工作岗位：其中1000个在罗氏，逾1.1万个将用于支持美国新的制造能力。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王永生","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-04-22/doc-inetzkuy0975363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2529315153","title":"康寧傑瑞製藥-B盤中異動 下午盤大幅上漲5.13%報6.970港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529315153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529315153?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:08","pubTimestamp":1745298535,"startTime":"0","endTime":"0","summary":"2025年04月22日下午盘13时08分，康宁杰瑞制药-B股票出现异动，股价大幅拉升5.13%。截至发稿，该股报6.970港元/股，成交量173.642万股，换手率0.18%，振幅6.49%。资金方面，该股资金流入449.36万港元，流出660.9万港元。康宁杰瑞制药-B股票所在的生物技术行业中，整体涨幅为4.59%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422130856aa2c759a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422130856aa2c759a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2529131345","title":"【羅氏未來五年將在美國投資500億美元】羅氏將在未來五年在美國製藥和診斷領域投資500億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529131345","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529131345?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:05","pubTimestamp":1745298312,"startTime":"0","endTime":"0","summary":"罗氏将在未来五年在美国制药和诊断领域投资500亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22130549742749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2529390432","title":"《股市簡訊》中國康方生物一度跳漲6.5%，首個自身免疫性疾病藥物獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2529390432","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529390432?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 12:28","pubTimestamp":1745296130,"startTime":"0","endTime":"0","summary":"《股市简讯》中国康方生物一度跳涨6.5%，首个自身免疫性疾病药物获批上市* 中国生物科技公司--康方生物9926.HK周二早盘一度升6.5%，早市收高5.6%。* 该公司此前公告称，中国国家药品监督管理局已于近日批准爱达罗的新药上市申请，用于治疗中度至重度斑块型银屑病成人患者。依若奇单抗是公司自身免疫性疾病领域首个获批上市的一类新药，也是第二个获批上市的非肿瘤新药。* 康方生物今年迄今劲涨44.2%，同期恒生指数.HSI上扬6.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL4T3R0091:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","BK1161","LU0348784397.USD","LU1720050803.USD","IE00B543WZ88.USD","LU0348783233.USD","LU0417516571.SGD","LU2488822045.USD","09926","LU1794554557.SGD"],"gpt_icon":0},{"id":"2529318189","title":"港股午評：恒生指數跌0.04% 黃金、創新藥板塊領漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2529318189","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529318189?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 12:17","pubTimestamp":1745295468,"startTime":"0","endTime":"0","summary":"南方财经4月22日电，港股午间收盘，恒生指数跌0.04%，恒生科技指数跌0.5%。黄金、创新药板块领涨，赤峰黄金、山东黄金涨超10%；歌礼制药-B涨近20%，药明生物涨超3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504223384185920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSTECH","HHImain","BK1574","MCHmain","02833","BK1161","HSI","06978","BK4614","YANG","513600"],"gpt_icon":0},{"id":"2529392335","title":"去年北京追回醫保基金4.64億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529392335","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529392335?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 11:47","pubTimestamp":1745293635,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","BK1161","159938","BK1515","09939"],"gpt_icon":0},{"id":"2529394377","title":"國信證券：關注出海加速的創新藥以及政策支持的服務板塊","url":"https://stock-news.laohu8.com/highlight/detail?id=2529394377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529394377?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 11:00","pubTimestamp":1745290808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，从2025年初以来，国产创新药企业已经完成了几十笔对外授权的交易，均与海外MNC达成了重磅交易。国产创新药的研发进度和临床数据越来越在全球范围内占到优势，创新药BD出海受关税影响较小，有望继续通过授权出海的形式实现全球的商业化价值。报告中称，2025年4月10日，国家医保局正式宣告中国医疗保险研究会生育保险专业委员会成立。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348784397.USD","BK1583","BK0183","IE00BPRC5H50.USD","06978","IE00B5MMRT66.SGD","LU1794554557.SGD","00013","BK1588","BK0028","BK0188","BK0276","LU1720050803.USD","BK1574","LU2488822045.USD","09926","BK1191","IE00B543WZ88.USD","02162","06990","LU0417516571.SGD","002736","BK1587","LU0196878994.USD","LU0348783233.USD","01530","BK1593","BK1161","159992"],"gpt_icon":0},{"id":"2529204399","title":"港股概念追蹤|生物醫藥去庫存週期尾聲        原料藥+創新藥受益國產替代（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2529204399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529204399?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:50","pubTimestamp":1745290214,"startTime":"0","endTime":"0","summary":"探索建立生物医药企业进口研发用物品“白名单”制度，允许免予办理进口药品通关单。中国由于工程师红利、环保及成本优势过往承接全球原料药生产重心转移，为全球主工厂之一。期内总收入为21亿元人民币，其中产品销售收入20亿元人民币，同比增长25%。机构预期康方生物今年的产品销售将同比增长60%至33亿元人民币，受惠今年初AK104和AK112被纳入中国国家医保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287792.SGD","LU1993786604.SGD","LU0072913022.USD","399441","09995","IE0008369823.USD","06978","IE00BZ08YT58.USD","LU0501845795.SGD","HSTECH","IE0008368742.USD","IE00B031HY20.USD","LU1152091754.HKD","LU1226288253.USD","IE00B5MMRT66.SGD","LU1807302812.USD","BK1515","LU0326950275.SGD","LU0067412154.USD","01093","IE00B543WZ88.USD","IE00BZ08YR35.GBP","SG9999004220.SGD","BK1161","LU1951186391.HKD","LU1969619763.USD","LU1226287875.USD","BK1521","LU1226287529.USD","LU2328871848.SGD","BK1574","BK1191","LU0140636845.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","BK4614","159992","LU1008478684.HKD","LU1960683339.HKD","YANG","BK1583","161726","LU1226288170.HKD"],"gpt_icon":1},{"id":"2529395377","title":"A股創新藥板塊震盪走高，華納藥廠漲超10%，熱景生物漲超7%，東誠藥業、百利天恆、翰宇藥業跟漲。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529395377","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529395377?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:40","pubTimestamp":1745289614,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159992","06978","300199","BK0028","BK0070","BK0077","BK0188","688068","002675","688799","BK1574","BK0239","159982","BK1161","399300","688506"],"gpt_icon":0},{"id":"2529397067","title":"沛嘉醫療-B盤中異動 早盤股價大漲5.63%報4.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529397067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529397067?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:25","pubTimestamp":1745288709,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘10时25分，沛嘉医疗-B股票出现波动，股价急速上涨5.63%。截至发稿，该股报4.880港元/股，成交量16.8万股，换手率0.03%，振幅5.63%。沛嘉医疗-B股票所在的医疗设备及用品行业中，整体涨幅为0.99%。其相关个股中，心泰医疗、堃博医疗-B、康基医疗涨幅较大，振幅较大的相关个股有心泰医疗、堃博医疗-B、心玮医疗-B，振幅分别为103.62%、16.98%、13.61%。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422102509aa2c757c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422102509aa2c757c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","09996","BK1574","BK1100"],"gpt_icon":0},{"id":"2529393646","title":"港股創新藥50ETF(513780)漲超3%，多隻個股漲超10%！多款創新藥取得突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2529393646","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529393646?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 10:21","pubTimestamp":1745288512,"startTime":"0","endTime":"0","summary":"消息面上，在医药创新赛道上，近一周包括诺诚健华、远大医药在内多家药企纷纷传来好消息，多款创新药的临床试验取得了关键进展，为全球患者带来了新的希望，也为医药行业的发展注入了强大动力。港股创新药50ETF跟踪中证港股通创新药指数，从港股通范围内选取业务涉及创新药研发以及为制药企业提供药物研究、开发和产等服务的股票。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.jrj.com.cn/2025/04/22102149738723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","06978","BK1161","513780","159992"],"gpt_icon":0}],"pageSize":20,"totalPage":28,"pageCount":2,"totalSize":549,"code":"91000000","status":"200"}]}}